NCT02222454已完成不适用
A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers
KLOX Technologies Inc.8 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2012年11月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 3
- 试验地点
- 8
- 主要终点
- Safety and tolerability of the KLOX BioPhotonic System in patients with stage II or III pressure ulcers.
研究概览
简要总结
The primary objective of these case series is to evaluate the safety and tolerability of the KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with stage II or III pressure ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female 18 years of age and older;
- •The subject or legal guardian must have signed an informed consent form;
- •Female of child bearing potential must have a negative pregnancy test result at Baseline and both male and female patients must be willing to adhere to a medically-accepted birth control method during the course of the study;
- •Willingness to return for all study visits;
- •Stage II or III pressure ulcer (as per NPUAP Staging Guidelines), present for more than 4 weeks (up to Screening visit), located in the ischial, trochanteric, coccygeal, thoracic or abdominal regions. Lower extremity pressure ulcers, such as heel ulcers, are acceptable provided that diabetic foot ulcers are ruled out if the patient has diabetes. Surface dimensions of ulcer must be between 2 to 64 cm2 inclusive but longest diameter must not exceed 10 cm. Depth must not exceed 5 cm;
- •Wound area has not changed by more than +/- 30% between Screening visit and Week 1/Visit 1 (before treatment).
排除标准
- •Pressure ulcer present for more than 18 months;
- •The ulcer to be treated is planned for operative debridement;
- •The ulcer has significant necrotic tissue (e.g., more than 20% of the ulcer area);
- •Major uncontrolled medical disorder(s) such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care or sickle cell anemia;
- •Severe or significant hypoalbuminemia (albuminemia < 30 g/L, and/or pre-albumin < 5 mg/dL), or hypoproteinemia (proteinemia < 55g/L);
- •Patient with moderate to severe anemia (Hb < 90g/L);
- •Patient currently treated for an active malignant disease;
- •Patient with history of malignancy within the wound;
- •Patient with history of radiation therapy to the wound region;
- •Patient with prior diagnosis of active malignant disease who is less than 1 year disease-free;
- •Patient with a known osteomyelitis or active cellulitis;
- •Patients that are immunosuppressed or on high dose chronic steroid use;
- •Patients on systemic corticosteroids (a completion of corticosteroid course at least 30 days prior to study enrolment is required);
- •Patient with active or systemic infection (note that the patient is however eligible for re-screening after the systemic infection has subsided);
- •Patients with severely uncontrolled diabetes mellitus (defined as A1C > 12%);
- •Dermatologic comorbid disease (e.g., cutis laxa or collagen vascular disease);
- •Active bleeding;
- •Pregnancy, or breast feeding;
- •Patients with bleeding diathesis;
- •Patients on Warfarin or IV Heparin;
- •The subject has any physical or psychiatric condition that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study (e.g., severe morbid obesity, recent hip fracture, suspected non-compliance, etc.);
- •Patients with ulcers from burns (from exposure to high heat), venous ulcers or diabetic foot ulcers;
- •Concurrent disease or drugs known to induce severe photosensitivity of the skin, such as porphyria;
- •Patient has received biological-based therapy in any wound within 3 months of Screening;
- •Concurrent participation in another clinical trial that involves an investigational drug or device that wound interfere with this study;
- •Previous participation in other interventional wound healing clinical investigation within the 60 days prior to Screening visit.
结局指标
主要结局
Safety and tolerability of the KLOX BioPhotonic System in patients with stage II or III pressure ulcers.
时间窗: 24 weeks
Occurrence of adverse events, serious adverse events and incidents; pain assessment with Visual Analog Scale; clinical laboratory parameters; vital signs; physical examination; percentage of patients with clinical infection requiring systemic antimicrobial therapy; concomitant medications and treatments.
次要结局
- Time to complete wound closure.(24 weeks)
- Incidence of wound breakdown.(24 weeks)
- Wound area reduction over time.(24 weeks)
- Optimal frequency of treatment with KLOX BioPhotonic System on stage II and III pressure ulcers.(24 weeks)
- Rate of complete wound closure.(24 weeks)
- Wound volume reduction over time.(24 weeks)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Safety Evaluation of the KLOX BioPhotonic System in Diabetic Foot UlcersDiabetic Foot UlcersNCT02222506KLOX Technologies Inc.10
已完成
不适用
Safety Evaluation of the KLOX BioPhotonic System in Venous Leg UlcersVenous Leg UlcersNCT02222467KLOX Technologies Inc.10
Unknown
3 期
Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having KeratoconusPost LASIK KeratectasiaKeratoconusNCT02638376Singapore Eye Research Institute66
Unknown
不适用
Safety and Performance of LeadExx LC System in Lead ExtractionImplant Site InfectionNCT02996929LeadExx Cardiac Ltd.10
已完成
1 期
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid TumorsNCT04047862BeiGene446